SHANGHAI OPM BIOSCIENCES CO., LTD. — Investor Relations & Filings
About SHANGHAI OPM BIOSCIENCES CO., LTD.
Shanghai OPM Biosciences Co., Ltd. specializes in the development of high-end cell culture media and the provision of comprehensive CDMO services. The company offers a diverse portfolio of serum-free media products tailored for various cell lines, including CHO, HEK293, and insect cells, supporting the production of recombinant proteins, antibodies, and vaccines. OPM provides end-to-end bioprocess development and manufacturing services, ranging from cell line development to pilot-scale production. By integrating media optimization with process engineering, the company aims to enhance yields and reduce costs for biopharmaceutical clients. Its technical platform focuses on high-performance formulations designed to meet rigorous regulatory standards and facilitate the transition from laboratory research to commercial-scale manufacturing.
Recent filings
| Filing | Released | Lang | Actions |
|---|---|---|---|
| 立信会计师事务所（特殊普通合伙）关于上海奥浦迈生物科技股份有限公司重大资产重组业绩承诺实现情况专项审核报告 | 2026-04-22 | Chinese | |
| 奥浦迈：2025年年度报告摘要 | 2026-04-22 | Chinese | |
| 奥浦迈：2025年度独立董事述职报告（张元兴） | 2026-04-22 | Chinese | |
| 奥浦迈：2025年度会计师事务所的履职情况评估报告 | 2026-04-22 | Chinese | |
| 奥浦迈：2025年度独立董事述职报告（李晓梅） | 2026-04-22 | Chinese | |
| 奥浦迈：关于2026年度董事、高级管理人员薪酬方案的公告 | 2026-04-22 | Chinese |
| ID | Filing | Released | Lang | Actions | |
|---|---|---|---|---|---|
|
2026
15 filings
| |||||
| 39525418 | 立信会计师事务所（特殊普通合伙）关于上海奥浦迈生物科技股份有限公司重大资产重组业绩承诺实现情况专项审核报告 | 2026-04-22 | Chinese | ||
| 39525344 | 奥浦迈：2025年年度报告摘要 | 2026-04-22 | Chinese | ||
| 39525342 | 奥浦迈：2025年度独立董事述职报告（张元兴） | 2026-04-22 | Chinese | ||
| 39525338 | 奥浦迈：2025年度会计师事务所的履职情况评估报告 | 2026-04-22 | Chinese | ||
| 39525337 | 奥浦迈：2025年度独立董事述职报告（李晓梅） | 2026-04-22 | Chinese | ||
| 39525334 | 奥浦迈：关于2026年度董事、高级管理人员薪酬方案的公告 | 2026-04-22 | Chinese | ||
| 39525331 | 奥浦迈：关于召开2025年年度股东会的通知 | 2026-04-22 | Chinese | ||
| 39525329 | 奥浦迈：关于重大资产重组之标的资产过渡期损益情况的公告 | 2026-04-22 | Chinese | ||
| 39525328 | 奥浦迈：董事、高级管理人员薪酬管理制度 | 2026-04-22 | Chinese | ||
| 39525325 | 奥浦迈：关于变更持续督导保荐代表人及持续督导独立财务顾问主办人的公告 | 2026-04-17 | Chinese | ||
| 39525323 | 上海奥浦迈生物科技股份有限公司发行股份及支付现金购买资产并募集配套资金实施情况暨新增股份上市公告书（摘要） | 2026-04-15 | Chinese | ||
| 39525321 | 上海奥浦迈生物科技股份有限公司发行股份及支付现金购买资产并募集配套资金实施情况暨新增股份上市公告书 | 2026-04-15 | Chinese | ||
| 39525319 | 奥浦迈：关于控股股东、实际控制人及部分持股5%以上股东权益被动稀释触及1%、5%刻度暨披露简式权益变动报告书的提示性公告 | 2026-04-15 | Chinese | ||
| 39525318 | 奥浦迈：简式权益变动报告书（华杰投资） | 2026-04-15 | Chinese | ||
| 39525316 | 奥浦迈：上海市方达律师事务所关于上海奥浦迈生物科技股份有限公司发行股份及支付现金购买资产并募集配套资金之实施情况的法律意见书 | 2026-04-15 | Chinese | ||
Market data
Market data not available
Price history
Peer group · Research and experimental development on natural sciences and engineering
| Company | Ticker | Country | Sector |
|---|---|---|---|
|
1NKEMIA
Biotechnology company providing R&D and services for the li…
|
IKM | ES | Professional, scientific and te… |
|
2cureX AB
Develops an IVD test using 3D tumoroids to predict patient …
|
2CUREX | SE | Professional, scientific and te… |
|
Abattis Bioceuticals Corp.
Life sciences company aggregating and investing in cannabis…
|
ATTBF | CA | Professional, scientific and te… |
|
Abera Bioscience AB
Develops mucosal vaccines using a proprietary Outer Membran…
|
ABERA | SE | Professional, scientific and te… |
|
ABION Inc.
Clinical-stage biopharma developing therapeutics for oncolo…
|
203400 | KR | Professional, scientific and te… |
|
ABL Bio Inc.
Develops bispecific antibody therapeutics for oncology and …
|
298380 | KR | Professional, scientific and te… |
|
Abnova (Taiwan) Corporation
Global leader in high-throughput production of antibodies a…
|
4133 | TW | Professional, scientific and te… |
|
Abpro Holdings, Inc.
Clinical-stage biotech developing antibody therapeutics for…
|
ABP | US | Professional, scientific and te… |
|
Absci Corp
A generative AI drug creation company developing biologic m…
|
ABSI | US | Professional, scientific and te… |
|
Achiko AG
A digital services platform for cross-border business compl…
|
ACHI | CH | Professional, scientific and te… |
SHANGHAI OPM BIOSCIENCES CO., LTD. via the API
Pull this company's filings, identifiers, and metadata as JSON or Markdown. Authenticate with your API key, then query by company ID, ISIN, or LEI. Full schema documented in the OpenAPI spec.
Endpoints
| GET | /api/companies/58310/ | Company identity, sector, listing, identifiers |
| GET | /api/filings/?company=58310 | Paginated list of all filings (filterable by type, date, language) |
| GET | /api/filings/{id}/ | Single filing — metadata, document URL, processing status |
| GET | /api/filings/{id}/markdown/ | Filing content as Markdown (PDF → text/tables/figures) |
| GET | /api/isins/?company=58310 | All ISINs registered to this company |
| GET | /api/filing-types/ | Reference: every filing-type code + category |
cURL
$ curl https://api.financialreports.eu/api/filings/?company=58310 \ -H "x-api-key: $FR_API_KEY" \ -H "Accept: application/json"
Python
import requests r = requests.get( "https://api.financialreports.eu/api/filings/", params={"company": 58310}, headers={"x-api-key": API_KEY}, ) filings = r.json()["results"]
MCP server
// MCP server URL https://mcp.financialfilings.com/mcp // Once connected, the LLM can query this company directly: "Pull the latest 5 filings for SHANGHAI OPM BIOSCIENCES CO., LTD. (id: 58310)"
Report missing filing
Can't find a specific document? Let us know and we'll add it within 24 hours.